|
|
|
| home > white papers > Analysis of Biopharmaceuticals to Conform to ICHQ6B - RSSL |
|
|
 WHITE PAPERS |
|
RSSL
|
+44 (0)118 918 4024
|
|
http://www.rssl.com
|
|
University of Reading, Whiteknights Rd, Reading, West Berkshire RG6 6LA
|
|
|
Analysis of Biopharmaceuticals to Conform to ICHQ6B
|
|
Worldwide, the pharmaceuticals market is anticipated to grow from more
than USD 782 billion in 2011 to approach a value of just over USD 971
billion by the end of 2016, registering a CAGR of over 24%. In 2010 the
average medicines expenditure per person within the UK was £271, and
this is expected to increase with the ageing population. A significant
and increasing proportion of these sales are protein-based
biotherapeutics or biomolecules. Currently, these account for 19% of the
total market, and are growing at twice the rate of traditional small
molecule pharmaceuticals. It is predicted that close to 50% of the top
100 pharmaceutical products will be biomolecules by 2016. By far the
largest segment of the biopharmaceutical market is the monoclonal
antibody (MAb) with an estimated share of 25.6%, which corresponds to
USD 51.1 billion.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Digital Manufacturing is a top priority for Life Sciences according to Zenith survey
Zenith Technologies, a world leader in delivering GMP manufacturing
software solutions to the life sciences industry, recently conducted an
industry survey that suggests the digital manufacturing is a top
priority.
More info >> |
|
 |
White Papers |
 |
|
Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models
DrugDev
For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality.
One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >> |
|
 |
Industry Events |
 |
Pharma Packaging and Labelling East Coast 2019
20-21 February 2019, Phildaelphia, USA
Now
in its 11th year, Pharma Packaging and Labeling is back to deliver key,
actionable insights into very latest regulatory requirements, technological
innovations, strategic developments, and how to implement them into your
packaging and labeling chain with both maximum efficiency and minimal cost.
More info >> |
|
|
|
